Sector News

Novartis to close Puerto Rico plant by 2019, move some operations to Lincoln plant

January 19, 2015
Life sciences
(AP) — Novartis AG is closing its manufacturing plant in Puerto Rico as part of a major overhaul of its business, the company said in a statement Friday.
 
The Switzerland-based company said the shutdown of its Humacao plant will conclude in early 2019. Some 270 employees will be laid off.
 
Novartis said it will transfer some manufacturing and packaging operations to companies including Eli Lilly & Co. Some operations also will be transferred to Novartis’ manufacturing plant in Lincoln, Nebraska.
 
Puerto Rico’s Industrial Development Company said it would seek to sell the plant to a local company or to one taking over some of Novartis’ operations.
 
The U.S. territory is still considered one of the world’s leading centers for pharmaceutical manufacturing, but the sector has been shrinking. The government has been offering incentives for manufacturing plants to expand and is pushing to diversify its manufacturing base by seeking aerospace and information technology companies.
 
Novartis’ Humacao plant opened in 1975.

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]